Yang states, “The aim of this review is to examine this indication from a clinician’s perspective, highlighting efficacy and safety results from the major trials with these novel oral agents. Clinical issues regarding bleeding, monitoring, and reversal are discussed, along with requirements to consider when interrupting treatment with a novel oral anticoagulant for the purpose of transitioning to another anticoagulant and prior to cardioversion, ablation, percutaneous coronary intervention, or emergency surgery.”

Studying elderly patients using Xarelto, Yang made some interesting conclusions. He writes, “Rivaroxaban was noninferior to warfarin (P<0.001) for reduction in the risk of stroke or systemic embolism in the intent-to-treat population; however, superiority was not shown. … The risk of intracranial hemorrhage was significantly lower with rivaroxaban, but the risk of gastrointestinal bleeding was significantly higher”. (emphasis added)

Due to the fact that Bayer has failed time and again to adequately warn users of this risk and does not advocate regular blood tests, Xarelto lawsuits are currently being filed in great number. If you or a loved one used Xarelto and suffered a major bleeding event, you may be entitled to significant financial compensation. For a free, no-obligation case consultation, contact our team of Xarelto lawyers at the information provided below. We have the experience, resources, and skills required to win the justice you deserve. Call today and see how we can help.

About this Blog

This blog chronicles legal and scientific news relating to personal injuries caused by defective drugs and medical devices. It is published by injury lawyer Justinian C. Lane, an attorney who takes a personal interest in each of his clients’ cases.